| Literature DB >> 34070643 |
Marco Casadio1, Francesca Biancaniello1, Diletta Overi2, Rosanna Venere1, Guido Carpino3, Eugenio Gaudio2, Domenico Alvaro1, Vincenzo Cardinale4.
Abstract
Cholangiocarcinomas (CCAs) are heterogeneous biliary tract malignancies with dismal prognosis, mainly due to tumor aggressiveness, late diagnosis, and poor response to current therapeutic options. High-throughput technologies have been used as a fundamental tool in unveiling CCA molecular landscape, and several molecular classifications have been proposed, leading to various targeted therapy trials. In this review, we aim to analyze the critical issues concerning the status of precision medicine in CCA, discussing molecular signatures and clusters, related to both anatomical classification and different etiopathogenesis, and the latest therapeutic strategies. Furthermore, we propose an integrated approach comprising the CCA molecular mechanism, pathobiology, clinical and histological findings, and treatment perspectives for the ultimate purpose of improving the methods of patient allocations in clinical trials and the response to personalized therapies.Entities:
Keywords: cholangiocarcinoma; molecular signatures; precision medicine; targeted therapy
Year: 2021 PMID: 34070643 DOI: 10.3390/ijms22115613
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923